The FDA just approved the first new schizophrenia drug in decades — a drug that ultimately succeeded because it once failed. It all goes back to Andrew Miller and the light bulb moment that led to his ...
Zacks Investment Research on MSN
Can recent traction with key drugs and pipeline progress boost BMY?
Bristol Myers Squibb BMY is undergoing a meaningful shift in its revenue mix, with its growth portfolio taking on a larger ...
The two-day gathering on precision therapeutics will be held at the Fralin Biomedical Research Institute at VTC.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results